Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 23 09 2023
accepted: 29 12 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: epublish

Résumé

Measuring body weight during therapy has received insufficient attention in poor resource settings like Ethiopia. We aimed to investigate the association between weight change during therapy and treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB) in northwest Ethiopia. This retrospective cohort study analysed data from patients with MDR-TB admitted between May 2015 to February 2022 at four treatment facilities in Northwest Ethiopia. We used the joint model (JM) to determine the association between weight change during therapy and treatment outcomes for patients with MDR-TB. A total of 419 patients with MDR-TB were included in the analysis. Of these, 265 (63.3%) were male, and 255 (60.9%) were undernourished. Weight increase over time was associated with a decrease in unsuccessful treatment outcomes (adjusted hazard ratio (AHR): 0.96, 95% CI: 0.94 to 0.98). In addition, patients with undernutrition (AHR: 1.72, 95% CI: 1.10 to 2.97), HIV (AHR:1.79, 95% CI: 1.04 to 3.06), and clinical complications such as pneumothorax (AHR: 1.66, 95% CI: 1.03 to 2.67) were associated with unsuccessful treatment outcomes. The JM showed a significant inverse association between weight gain and unsuccessful MDR-TB treatment outcomes. Therefore, weight gain may be used as a surrogate marker for good TB treatment response in Ethiopia.

Identifiants

pubmed: 38177234
doi: 10.1038/s41598-023-51026-y
pii: 10.1038/s41598-023-51026-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

508

Informations de copyright

© 2024. The Author(s).

Références

WHO. Global Tuberculosis Report. 2022.
Pai, M. & Memish, Z. A. Antimicrobial resistance and the growing threat of drug-resistant tuberculosis. J. Epidemiol. Glob. Health 6, 45 (2016).
pubmed: 26896704 pmcid: 7320441 doi: 10.1016/j.jegh.2016.02.001
Uplekar, M. et al. WHO’s new end TB strategy. The Lancet 385, 1799–1801 (2015).
doi: 10.1016/S0140-6736(15)60570-0
Falzon, D. et al. Multidrug-resistant tuberculosis around the world: What progress has been made?. Eur Respir J 45, 150–160 (2015).
pubmed: 25261327 doi: 10.1183/09031936.00101814
WHO. Global tuberculosis report. Geneva. 2019.
Singh, R. et al. Recent updates on drug resistance in Mycobacterium tuberculosis. J. Appl. Microbiol. 128, 1547–1567 (2020).
pubmed: 31595643 doi: 10.1111/jam.14478
Kendall, E., Fofana, M. & Dowdy, D. Burden of transmitted multidrug resistance in epidemics of tuberculosis: A transmission modelling analysis. Lancet Respir. Med. 3, 963–972 (2015).
pubmed: 26597127 pmcid: 4684734 doi: 10.1016/S2213-2600(15)00458-0
Mandelbaum-Schmid, J. The global plan to stop TB 2011–2015: transforming the fight towards elimination of tuberculosis (2011).
Dheda, K. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir. Med. 5, 291–360 (2017).
doi: 10.1016/S2213-2600(17)30079-6
Piubello, A. et al. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. Respir. Med. 161, 105844 (2020).
pubmed: 32056722 doi: 10.1016/j.rmed.2019.105844
Kang, Y. et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: Comparison of pre-and post-public–private mix periods. Tuberc. Respir. Dis 84, 74 (2021).
doi: 10.4046/trd.2020.0093
Aibana, O. et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC Infect. Dis. 17, 1–7 (2017).
doi: 10.1186/s12879-017-2230-2
Ketema, D. B., Muchie, K. F. & Andargie, A. A. Time to poor treatment outcome and its predictors among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara region, Ethiopia: Retrospective cohort study. BMC Public Health 19, 1–10 (2019).
doi: 10.1186/s12889-019-7838-2
Kang, Y. A. et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration 86, 472–478 (2013).
pubmed: 23689646 doi: 10.1159/000348374
Chung-Delgado, K., Guillen-Bravo, S., Revilla-Montag, A. & Bernabe-Ortiz, A. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS ONE 10, e0119332 (2015).
pubmed: 25790076 pmcid: 4366185 doi: 10.1371/journal.pone.0119332
Wagnew, F., Alene, K. A., Kelly, M. & Gray, D. The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: A systematic review and meta-analysis. Int. J. Infect. Dis. 127, 93–105 (2022).
pubmed: 36481489 doi: 10.1016/j.ijid.2022.11.043
Bade, A. B., Mega, T. A. & Negera, G. Z. Malnutrition is associated with delayed sputum culture conversion among patients treated for MDR-TB. Infect. Drug Resist. 14, 1659–1667 (2021).
pubmed: 33953577 pmcid: 8089472 doi: 10.2147/IDR.S293461
Bhargava, A., Bhargava, M., Pande, T., Rao, R. & Parmar, M. N-TB: A mobile-based application to simplify nutritional assessment, counseling and care of patients with tuberculosis in India. Indian J. Tuberc. 66, 193–196 (2019).
pubmed: 30878068 doi: 10.1016/j.ijtb.2018.10.005
Kant, S., Gupta, H. & Ahluwalia, S. Significance of nutrition in pulmonary tuberculosis. Crit. Rev. Food Sci. Nutr. 55, 955–963 (2015).
pubmed: 24915351 doi: 10.1080/10408398.2012.679500
WHO. Guideline: nutritional care and support for patients with tuberculosis. World Health Organization (2013).
FMOH. Guidelines for Clinical and Programmatic Management of TB, TB/HIV, DR-TB and Leprosy in Ethiopia (2021).
Vasantha, M., Gopi, P. & Subramani, R. Weight gain in patients with tuberculosis treated under directly observed treatment short-course (DOTS). India Indian J. Tuberc. 56, 5–9 (2009).
pubmed: 19402266
Bernabe-Ortiz, A., Carcamo, C. P., Sanchez, J. F. & Rios, J. Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. PLoS ONE 6, e18474 (2011).
pubmed: 21494617 pmcid: 3072983 doi: 10.1371/journal.pone.0018474
Rohini, K., Bhat, S., Srikumar, P., Saxena, J. & Kumar, M. Body weight gain in pulmonary tuberculosis during chemotherapy. Int. J. Collab. Res. Intern. Med. Public Health 5, 1–3 (2013).
Phan, M. N., Guy, E. S., Nickson, R. N. & Kao, C. C. Predictors and patterns of weight gain during treatment for tuberculosis in the United States of America. Int. J. Infect. Dis. 53, 1–5 (2016).
pubmed: 27693292 doi: 10.1016/j.ijid.2016.09.006
Parande, M. A., Borle, P. S., Tapare, V. S., More, S. W. & Bhattacharya, S. S. Change in body weight and treatment outcome in sputum positive pulmonary tuberculosis patients treated under directly observed treatment short-course. Int. J. Community Med. Public Health 5, 2431–2436 (2018).
doi: 10.18203/2394-6040.ijcmph20182172
Khan, A., Sterling, T. R., Reves, R., Vernon, A., & Horsburgh, C. R., Consortium TT. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am. J. Respir. Crit. Care Med. 174, 344–348 (2006).
Fewell, Z. et al. Controlling for time-dependent confounding using marginal structural models. The Stata J. 4, 402–420 (2004).
doi: 10.1177/1536867X0400400403
Asar, Ö., Ritchie, J., Kalra, P. A. & Diggle, P. J. Joint modelling of repeated measurement and time-to-event data: An introductory tutorial. Int. J. Epidemiol. 44, 334–344 (2015).
pubmed: 25604450 doi: 10.1093/ije/dyu262
Ibrahim, J. G., Chu, H. & Chen, L. M. Basic concepts and methods for joint models of longitudinal and survival data. J. Clin. Oncol. 28, 2796 (2010).
pubmed: 20439643 pmcid: 4503792 doi: 10.1200/JCO.2009.25.0654
Baluku, J. B., Namiiro, S. & Nabwana, M. Undernutrition and treatment success in drug-resistant Tuberculosis in Uganda. Infect. Drug Resist. 14, 3673–3681 (2021).
pubmed: 34526787 pmcid: 8437412 doi: 10.2147/IDR.S332148
Molalign, S. & Wencheko, E. Risk factors of mortality in patients with multi-drug resistant TB. J. Health Dev. 29, 82–88 (2015).
Wakjira, M. K., Sandy, P. T. & Mavhandu-Mudzusi, A. H. Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia. PLoS ONE 17, e0262318 (2022).
pubmed: 35176035 pmcid: 8853509 doi: 10.1371/journal.pone.0262318
Bogale, L., Tsegaye, T., Abdulkadir, M. & Akalu, T. Y. Unfavorable treatment outcome and its predictors among patients with multidrug-resistance tuberculosis in Southern Ethiopia in 2014 to 2019: a multi-center retrospective follow-up study. Infect. Drug Resist. 14, 1343–1355 (2021).
pubmed: 33854347 pmcid: 8041603 doi: 10.2147/IDR.S300814
Li, C. Little’s test of missing completely at random. Stata J. 13, 795–809 (2013).
doi: 10.1177/1536867X1301300407
Wu, L., Liu, W., Yi, G. Y. & Huang, Y. Analysis of longitudinal and survival data: joint modeling, inference methods, and issues. J. Probab. Stat. 2012 (2012).
Henderson, R., Diggle, P. & Dobson, A. Joint modelling of longitudinal measurements and event time data. Biostatistics 1, 465–480 (2000).
pubmed: 12933568 doi: 10.1093/biostatistics/1.4.465
Woldeyohannes, D., Assefa, T., Aman, R., Tekalegn, Y. & Hailemariam, Z. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia. PLoS ONE 14, e0224025 (2019).
pubmed: 31665154 pmcid: 6821088 doi: 10.1371/journal.pone.0224025
Li, D., Ge, E., Shen, X. & Wei, X. Risk factors of treatment outcomes for multi-drug resistant tuberculosis in Shanghai, 2009–2012. Procedia Environ. Sci. 36, 12–19 (2016).
doi: 10.1016/j.proenv.2016.09.003
Shean, K. et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992–2002. Int. J. Tuberc. Lung Dis. 12(10), 1182–1189 (2008).
pubmed: 18812049
Nair, D. et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Health Action. 7, 32–38 (2017).
pubmed: 28775941 pmcid: 5526484 doi: 10.5588/pha.16.0055
El Hamdouni, M. et al. Treatment outcomes of drug resistant tuberculosis patients in Morocco: Multi-centric prospective study. BMC Infect. Dis. 19, 1–7 (2019).
doi: 10.1186/s12879-019-3931-5
Bastard, M. et al. Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. J. Infect. Dis. 211, 1607–1615 (2015).
pubmed: 25312040 doi: 10.1093/infdis/jiu551
Ali, M. H. et al. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Rev. Anti Infect. Ther. 17, 927–937 (2019).
pubmed: 31689134 doi: 10.1080/14787210.2019.1689818
Kibret, K. T., Moges, Y., Memiah, P. & Biadgilign, S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: A systematic review and meta-analysis of published studies. Infect. Dis. Poverty 6, 1–8 (2017).
doi: 10.1186/s40249-016-0214-x
WHO. WHO consolidated guidelines on tuberculosis: Module 4: treatment: drug-resistant tuberculosis treatment: online annexes (2020).
Toczek, A., Cox, H., Du Cros, P., Cooke, G. & Ford, N. Strategies for reducing treatment default in drug-resistant tuberculosis: Systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 17, 299–307 (2013).
pubmed: 23211716 doi: 10.5588/ijtld.12.0537
Gler, M. T. et al. Weight gain and response to treatment for multidrug-resistant tuberculosis. Am. J. Trop. Med. Hyg. 89, 943 (2013).
pubmed: 24019430 pmcid: 3820341 doi: 10.4269/ajtmh.13-0011
Hoa, N., Lauritsen, J. & Rieder, H. Changes in body weight and tuberculosis treatment outcome in Viet Nam. Int. J. Tuberc. Lung. Dis. 17, 61–66 (2013).
pubmed: 23146565 doi: 10.5588/ijtld.12.0369
Peetluk, L. S. et al. Lack of weight gain during the first 2 months of treatment and human immunodeficiency virus independently predict unsuccessful treatment outcomes in tuberculosis. J. Infect. Dis. 221, 1416–1424 (2020).
pubmed: 31724035 doi: 10.1093/infdis/jiz595
Kurbatova, E. V. et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis 92, 397–403 (2012).
pubmed: 22789497 doi: 10.1016/j.tube.2012.06.003
Oxlade, O., Huang, C.-C. & Murray, M. Estimating the impact of reducing under-nutrition on the tuberculosis epidemic in the central eastern states of India: A dynamic modeling study. PLoS ONE 10, e0128187 (2015).
pubmed: 26046649 pmcid: 4457886 doi: 10.1371/journal.pone.0128187
McMurray, D. Cell-mediated immunity in nutritional deficiency. Prog. Food Nutr. Sci. 8, 193–228 (1984).
pubmed: 6396715
Sinha, P. et al. Food for thought: addressing undernutrition to end tuberculosis. Lancet Infect. Dis. 21, e318–e325 (2021).
pubmed: 33770535 pmcid: 8458477 doi: 10.1016/S1473-3099(20)30792-1
Byrd, R. P. Jr., Mehta, J. B. & Roy, T. M. Malnutrition and pulmonary tuberculosis. Clin. Infect. Dis. 35, 634–635 (2002).
pubmed: 12173145 doi: 10.1086/342314
Sayem, M. A., Hossain, M. G., Ahmed, T., Hossain, K. & Saud, Z. A. Effect of nutritional support on treatment of multi-drug resistant tuberculosis in Rajshahi Division, Bangladesh. J. Tuberc. Res. 8, 223 (2020).
doi: 10.4236/jtr.2020.84020
Van Hout, M. C. & Hope, V. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: A systematic review and meta-analysis. BMC Infect. Dis. 19, 1–8 (2019).
Singh, A., Prasad, R., Balasubramanian, V. & Gupta, N. Drug-resistant tuberculosis and HIV infection: Current perspectives. HIV/AIDS (Auckland, NZ). 12, 9 (2020).
Semvua, H. H. et al. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther. Drug Monit. 37, 22–32 (2015).
pubmed: 24943062 doi: 10.1097/FTD.0000000000000108
Girum, T., Tariku, Y. & Dessu, S. Survival status and treatment outcome of multidrug resistant tuberculosis (MDR-TB) among patients treated in treatment initiation centers (TIC) in South Ethiopia: A retrospective cohort study. Ann. Med. Health Sci. Res. 7 (2017).

Auteurs

Fasil Wagnew (F)

College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia. FasilWagnew.Shiferaw@anu.edu.au.
National Centre for Epidemiology and Population Health (NCEPH), College of Health and Medicine, The Australian National University, Canberra, Australia. FasilWagnew.Shiferaw@anu.edu.au.
Geospatial and Tuberculosis Research Team, Telethon Kids Institute, Nedlands, WA, Australia. FasilWagnew.Shiferaw@anu.edu.au.

Kefyalew Addis Alene (KA)

Geospatial and Tuberculosis Research Team, Telethon Kids Institute, Nedlands, WA, Australia.
School of Population Health, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.

Matthew Kelly (M)

National Centre for Epidemiology and Population Health (NCEPH), College of Health and Medicine, The Australian National University, Canberra, Australia.

Darren Gray (D)

Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Classifications MeSH